Back to Newsroom

StemCells, Inc. Publishes Comprehensive Review of Results From HuCNS-SC Clinical Trials

NEWARK, Calif., Sept. 9, 2013 — StemCells, Inc. (Nasdaq:STEM) today announced the publication of a comprehensive overview describing the therapeutic potential and results from early clinical trials of the Company’s proprietary HuCNS-SC(R) product candidate (purified human neural stem cells).